Arena Pharmaceuticals Inc.
www.arenapharm.com
Latest From Arena Pharmaceuticals Inc.
Axovant Closes Chapter On Failed, Second-Rate Small Molecule Strategy
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate
With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.
Genkyotex Plans 'Solo' Pivotal Trials After Lead Product Hits Phase II PBC Targets
The CEO Genkyotex says its lead molecule therapy's mechanism of action has been validated by good short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cardiovascular
- Gastrointestinal
- Immune Disorders
- Metabolic Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Arena Pharmaceuticals Inc.
- Senior Management
-
Amit Munshi, Pres. & CEO
Kevin R Lind, EVP, CFO
Vince Aurentz, EVP, CBO
Preston Klassen, MD, EVP, R&D & CMO - Contact Info
-
Arena Pharmaceuticals Inc.
Phone: (858) 453-7200
6154 Nancy Ridge Dr.
San Diego, CA 92121
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice